Clinicaltrials.gov identifier:
NCT03805919
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Study Contact Information:
Anna Couvillon, Nurse Practitioner
By phone: (240) 858-3148
or by email
Screening Study for Men at High Genetic Risk for Prostate Cancer
About the Study
The National Cancer Institute opened a clinical trial for cancer screening in men who are at high risk for cancer due to an .
View the study on ClinicalTrials.gov or contact Anna Couvillon, NP at: (240) 858-3148 or by email.
What the Study Entails
- Screening of the every 2 years
- Annual blood test
- Biopsy of the if any MRIs are abnormal
- No cost for study-related tests or procedures
- No cost for travel
- Clinical information will be shared with you and your doctor, if you choose
- Genetic testing is not offered as part of the study
Study Lead Investigator
Fatima Karzai, MD, National Cancer Institute (NCI)
can cover the cost of travel for participants
Maryland
City: Bethesda RECRUITING
Facility: National Institutes of Health Clinical Center
Contact Info:
[email protected]
800-411-1222
Men, and people assigned male at birth are eligible if they:
- are between the ages 30 - 75 years old
- do not have cancer, and
- have had genetic testing and have any of the following: (, , , , ), , , , , , , , , , , , or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM) mutation.
- People who have already been diagnosed with cancer